Polycystic ovary syndrome. polycystic ovarian syndrome
Conditions
Interventions
Intervention 1: Capsules containing 500 mg of cinnamon powder, 3 times a day (morning, afternoon, evening), after a meal with a standard treatment regimen (10 mg medroxyprogesterone tablets?from the 1
Treatment - Drugs
Capsules containing 500 mg of cinnamon powder, 3 times a day (morning, afternoon, evening), after a meal with a standard treatment regimen (10 mg medroxyprogesterone tablets?from the 15th day of menst
Control group: contains starch as placebo capsules, 3 times a day (morning, afternoon, evening), after a meal with a standard treatment regimen (10 mg medroxyprogesterone tablets?from day 15 of the me
Sponsors
Vice chancellor for research,Shiraz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: informed consent to participate in the study? polycystic ovary syndrome diagnostic criteria Rotterdam are two of three of the following symptoms: i abnormal menstrual cycles (oligo dysmenorrhea, amenorrhea) ii polycystic ovaries on ultrasound iii clinical signs of hyperandrogenism (hirsutism -acne-) or biochemical signs of hyperandrogenism and also reject and Cushing's syndrome and congenital adrenal hyperplasia? age 45-18 years ?Body mass index (BMI) greater than or equal to 18. Exclusion criteria: any disease affecting variables (diabetes, liver disease, thyroid, cardiovascular, renal, gastrointestinal, Cushing's syndrome, adrenal hyperplasia, androgen-secreting tumors, hyperprolactinemia) based on the patient's previous history? Taking blood pressure medications or statins or anti-diabetic drugs and insulin injections ?Pregnancy ?Breast-feeding ?use of any vitamin supplements, minerals and hormones for at least two months before the study ?being under the special diet ?Consumers oral contraceptives (OCP), glucocorticoids, anti-androgens, ovulation induction drugs ?consumers of tobacco and alcohol ?a history of allergy to cinnamon
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Weight, body mass index, waist and hip. Timepoint: Before study and after 12 weeks. Method of measurement: questionnaire.;Fasting blood glucose, two hour blood glucose, serum insulin levels, lipid profile. Timepoint: Before study and after 12 weeks. Method of measurement: Blood sample.;Serum androgen levels. Timepoint: Before study and after 12 weeks. Method of measurement: Blood sample. | — |
Secondary
| Measure | Time frame |
|---|---|
| The menstrual cycle regularity. Timepoint: Before study and after 12 weeks. Method of measurement: Questions from Patients. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMahdie Hajimonfared
Shiraz University of medical science
Outcome results
None listed